The library will be closed between August 10, 2026 and August 16, 2026. During this period, it will be possible to upload publications, but all other services will be suspended.
Csizmarik, A.,
Nagy, N.,
Keresztes, D.,
Váradi, M.,
Bracht, T.,
Sitek, B.,
Witzke, K.,
Puhr, M.,
Tornyi, I.,
Lázár, J.,
Takács, L.,
Kramer, G.,
Sevcenko, S.,
Maj-Hes, A.,
Hadaschik, B.,
Nyirády, P.,
Szarvas, T.:
Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis. 2025, 1-2, 2025.
Nagy, N.,
Bói, B.,
Papp, G.,
Fiák, E.,
Gáspár-Kiss, E.,
Perge, B.,
Farmasi, N.,
Tarr, T.:
Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus.
Biomedicines. 12 (3), 1-15, (article identifier: 530), 2024.
Q1
Biochemistry, Genetics and Molecular Biology (miscellaneous)
Q1
Medicine (miscellaneous)
3.
Perge, B.,
Papp, G.,
Bói, B.,
Nagy, N.,
Gáspár-Kiss, E.,
Tarr, T.:
Clinical Features and Survival Analysis of Lupus Nephritis among Patients with Systemic Lupus Erythematosus: a Three-Decade-Long Retrospective Cohort Study.
Biomedicines. 12 (9), 1-17, (article identifier: 2117), 2024.
Q1
Biochemistry, Genetics and Molecular Biology (miscellaneous)
Q1
Medicine (miscellaneous)
2023
4.
Nagy, N.,
Papp, G.,
Gáspár-Kiss, E.,
Diószegi, Á.,
Tarr, T.:
Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades.
Biomedicines. 11 (4), 1-10, (article identifier: 1218), 2023.
Q1
Biochemistry, Genetics and Molecular Biology (miscellaneous)
Q1
Medicine (miscellaneous)
2022
5.
Szabó, K.,
Jámbor, I.,
Pázmándi, K. L.,
Nagy, N.,
Papp, G.,
Tarr, T.:
Altered Circulating Follicular T Helper Cell Subsets and Follicular T Regulatory Cells Are Indicators of a Derailed B Cell Response in Lupus, Which Could Be Modified by Targeting IL-21R.
Int. J. Mol. Sci. 23 (20), 1-20, (article identifier: 12209), 2022.
Tarr, T.,
Papp, G.,
Nagy, N.,
Cserép, E.,
Zeher, M.:
Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.
Clin. Rheumatol. 36 (2), 327-333, 2017.
